User profiles for Gabriel C. Léger
 | Gabriel LégerUCSD Verified email at ucsd.edu Cited by 2831 |
Alzheimer's disease
JAS Lopez, HM González, GC Léger - Handbook of clinical neurology, 2019 - Elsevier
Alzheimer's disease (AD) dementia refers to a particular onset and course of cognitive and
functional decline associated with age together with a particular neuropathology. It was first …
functional decline associated with age together with a particular neuropathology. It was first …
Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia
…, N Johnson, E Rogalski, GC Léger… - Annals of Neurology …, 2008 - Wiley Online Library
Objective To identify predictors of Alzheimer's disease (AD) versus frontotemporal lobar
degeneration pathology in primary progressive aphasia (PPA), and determine whether the AD …
degeneration pathology in primary progressive aphasia (PPA), and determine whether the AD …
Pharmacological treatment of Alzheimer disease
F Massoud, GC Léger - The Canadian Journal of Psychiatry, 2011 - journals.sagepub.com
Objective: To review the different pharmacological approaches to the cognitive, functional,
and behavioural manifestations of Alzheimer disease (AD). Methods: We searched and …
and behavioural manifestations of Alzheimer disease (AD). Methods: We searched and …
Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans
Like native DOPA, [ 18 F]-6-fluoro-l-3,4-dihydroxyphenylalanine ([ 18 F]FDOPA) is subject to
methylation and decarboxylation. To determine the rates of formation and elimination of [ 18 …
methylation and decarboxylation. To determine the rates of formation and elimination of [ 18 …
Striatal L‐dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis
L‐DOPA is a large neutral amino acid subject to transport out of, as well as into, brain tissue.
Competition between dopamine synthesis and L‐DOPA egress from striatum must favor L‐…
Competition between dopamine synthesis and L‐DOPA egress from striatum must favor L‐…
[HTML][HTML] Comparing the electronic and standard versions of the Montreal Cognitive Assessment in an outpatient memory disorders clinic: a validation study
JL Berg, J Durant, GC Léger… - Journal of …, 2018 - content.iospress.com
The Montreal Cognitive Assessment (MoCA) has become widely used as a brief test of cognitive
function in patients with neurological disease. More convenient application of the MoCA …
function in patients with neurological disease. More convenient application of the MoCA …
[HTML][HTML] Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia
Background: Behavioral variant frontotemporal dementia (bvFTD) is pathologically
heterogeneous. With emerging therapeutics, determining underlying pathology during life is …
heterogeneous. With emerging therapeutics, determining underlying pathology during life is …
[PDF][PDF] Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders
Frontotemporal dementia (FTD) therapy development is hamstrung by a lack of susceptibility,
diagnostic, and prognostic biomarkers. Blood neurofilament light (NfL) shows promise as a …
diagnostic, and prognostic biomarkers. Blood neurofilament light (NfL) shows promise as a …
Association of Neurofibrillary Tangle Distribution With Age at Onset–Related Clinical Heterogeneity in Alzheimer Disease: An Autopsy Study
Background and Objective Patients with earlier age at onset of sporadic Alzheimer disease (AD)
are more likely than those with later onset to present with atypical clinical and cognitive …
are more likely than those with later onset to present with atypical clinical and cognitive …
[PDF][PDF] Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease
Mthods: We measured blood-brainbarriertransport and de carboxylatlonof 6-[1@ I9fIUOrO-L-DOPA
(FDOPA) usingPET in patientswith Parkinson'sdisease (n= 7, 57 ±7 yr) and age …
(FDOPA) usingPET in patientswith Parkinson'sdisease (n= 7, 57 ±7 yr) and age …